Future vs Labcorp
Side-by-side comparison of AI visibility scores, market position, and capabilities
Future pairs members with 130+ expert human coaches at $199/month using Apple Watch biometrics; 4.9-star rated app with $108M raised ($75M Series C). Founded 2017, San Francisco.
About
Future was founded in 2017 in San Francisco with the mission of making expert personal training accessible to anyone, not just athletes or the wealthy who can afford in-person coaching. The company built a digital personal training platform that pairs each member with a dedicated human coach who designs individualized workout plans, monitors progress through Apple Watch biometric data, and provides real-time feedback through the app. Future's core philosophy is that accountability and personalization — not generic content — are what actually drive sustained behavior change and fitness results.\n\nFuture's platform pairs members with more than 130 expert coaches who have backgrounds in strength and conditioning, sports performance, and clinical exercise science. Coaches review member activity daily, adjust programming based on recovery and performance data, and communicate directly through the app — creating a relationship-driven coaching model at digital scale. The service is priced at $199 per month, positioning it as a premium alternative to both in-person personal training and algorithm-driven fitness apps. Future integrates deeply with Apple Watch to capture heart rate, workout metrics, and activity data, giving coaches objective performance signals to inform programming decisions.\n\nFuture has raised $108 million in total, including a $75 million Series C, and maintains a 4.9-star rating in the App Store across tens of thousands of reviews — a remarkable signal of member satisfaction in a category often plagued by high churn. The company's human-plus-AI coaching model occupies a distinct position between the low-cost digital fitness market and the high-cost in-person coaching market, and its 130-plus coach network gives it a proprietary talent asset that is difficult to replicate. As demand for personalized health and longevity programs grows among high-income professionals, Future's model scales coach capacity through AI-assisted tools while preserving the relational quality that drives retention.
Burlington NC clinical laboratory services (NYSE: LH) ~$13.1B FY2024 revenue; Fortrea CRO spun off 2023, 2000+ PSC network, specialty oncology molecular testing competing with Quest Diagnostics.
About
Laboratory Corporation of America Holdings (Labcorp) is a Burlington, North Carolina-based clinical laboratory and life sciences company — publicly traded on the New York Stock Exchange (NYSE: LH) as an S&P 500 Health Care component — providing diagnostic laboratory testing services for physicians, hospitals, health systems, and patients across the United States and internationally, and providing drug development laboratory services (biopharmaceutical clinical trial laboratory support) through approximately 60,000 employees. In fiscal year 2024, Labcorp reported revenues of approximately $13.1 billion from the Diagnostics segment — following the June 2023 separation of its Drug Development segment as Fortrea Holdings (NASDAQ: FTRE), an independent public company providing CRO (contract research organization) services to pharmaceutical and biotech clients. CEO Adam Schechter has focused the post-Fortrea Labcorp on the pure-play diagnostics business: clinical testing across 6,000+ test menu items (routine blood work, specialty genetic testing, toxicology, and anatomic pathology) processed at Labcorp's 2,000+ patient service centers and sent to regional and specialty reference laboratories for results reporting to ordering physicians. The Labcorp consumer-direct testing initiative (at-home specimen collection kits for STI testing, COVID testing, and other direct-to-consumer tests ordered at labcorp.com without physician referral) expands beyond the traditional physician-ordered testing model to capture the growing consumer health testing market. Labcorp's specialty testing portfolio (oncology genomic profiling, rare disease genetic panels, prenatal cell-free DNA testing, advanced cardiac biomarker panels) generates higher revenue per requisition than routine chemistry and hematology panels — driving mix shift toward specialty and molecular testing revenue.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.